RBC Capital upgrades Lakefront Biotherapeutics to Outperform, sets $45 price target
RBC Capital upgraded Lakefront Biotherapeutics's stock to Outperform with a price target of $45.00.The price target implies an upside of 70.7% from the Sep 22 close of $26.36.Key takeaways from the analyst notePromising Drug Pipeline: Lakefront Biotherapeutics has a robust pipeline, particularly wi…